<DOC>
	<DOCNO>NCT00172133</DOCNO>
	<brief_summary>This Open Label Extension Study ( OLES ) patient participate 18 month double-blind , placebo-controlled , Phase III trial ( Protocol ALX1 11 93001 TOP Study ) study effect ALX1-11 , recombinant human parathyroid hormone , rhPTH ( 1-84 ) , vertebral fracture incidence . The primary objective study evaluate safety continue dose ALX1-11 , maximum 24 month , postmenopausal osteoporotic woman participate Protocol ALX1 11 93001 .</brief_summary>
	<brief_title>Open Label Extension Study PREOS</brief_title>
	<detailed_description>Effects ALX1-11 bone mineral density ( BMD ) document dose-finding Phase II clinical trial osteoporotic postmenopausal woman , supplement calcium Vitamin D3 without treatment osteoporosis . The anabolic effect ALX1-11 lumbar vertebra statistically significant 12-month treatment period pronounce approved therapy . Additionally , animal study show new bone form treatment ALX1 11 good quality histologically biomechanically . The primary objective OLES evaluate safety continue dose ALX1-11 , maximum 24 month , postmenopausal osteoporotic woman participate Protocol ALX1-11-93001 . A secondary objective ass change vertebral BMD compare change observe patient receive ALX1-11 placebo Protocol ALX1-11-93001 . Patients receive 100 µg/day ALX1-11 daily via subcutaneous injection study . Patients continue study drug dose frequency follow end Protocol ALX1-11-93001 . To enhance safety , patient continue take daily supplement 700 mg calcium 400 IU Vitamin D3 prior OLES . Patients whose calcium supplement discontinue Protocol ALX1-11-93001 maintain discontinuation OLES . However upon completion ALX1-11 dosing OLES , oral calcium supplement dose 700 mg morning restart maintain remainder OLES . Additional supplemental calcium and/or Vitamin D3 permit . A daily multivitamin supplement may take study . However , multivitamin must contain 200 mg/day calcium 400 IU/day Vitamin D3 . Patients monitor development hypercalcemia and/or hypercalciuria manage described Appendices 4 5 . There stop rule OLES . Any patient reach BMD T score -0.5 , site site ( vertebral , total hip , femoral neck ) use qualification patient Protocol ALX1 11-93001 , stop ALX1-11 treatment . The patient must continue calcium Vitamin D3 follow remainder 18-month OLES . At time discontinuation , patient must complete Month 18 evaluation ( Appendix 1A 1B ) . The Clinical Advisory Board ( CAB ) use Protocol ALX1-11-93001 involve review patient issue arise OLES . This group provide continuity care patient , also enhance consistent safety monitoring patient participate OLES .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Women complete 18 month treatment Protocol ALX11193001 ; Women prematurely discontinue Protocol ALX11193001 want participate OLES event list must clinical course review approved CAB enrollment OLES : Clinical incident lumbar vertebral fracture assess central image organization Clinical incident hip fracture Confirmed bone loss A/P lumbar vertebra total hip femoral neck assess central image organization Body weight 40 kg Development exclusion criterion Protocol ALX11193001 It must accept patient whose clinical course review CAB participation OLES may require additional test baseline and/or study ensure utmost safety . Women ability selfadminister daily injection designee give injection ; Women capable understand give write , voluntary inform consent start openlabel dose ALX111 . A . History Concurrent Illness : Disorders Immunity Endocrine system Gastrointestinal system Kidney collect system Liver , biliary tract pancreatic system Musculoskeletal system Patients chronic , active joint disease require one intraarticular injection every 6 month Neoplasia Patients squamous basal cell carcinoma skin may enter study : 1 . The lesion ( ) fully resect clear margin describe write report pathologist , 2 . The patient recurrence lesion least one year time original resection . Nervous system Vascular , respiratory cardiac system *Significant diseases disorder determine history , physical exam laboratory test judge Principal Investigator significant . B. Concurrent Medication : Patients may use follow therapy enrol OLES without permission Sponsor PMO : Tetracycline antibiotic four week prior bone biopsy Any PTH analog [ e.g. , rhPTH ( 184 ) , PTH ( 134 ) , PTHrP analogs ] Fluoride Strontium Phenytoin seizure control Any investigational drug ALX111 Anabolic steroid androgens Active Vitamin D3 metabolites analog , e.g. , calcitriol Systemic corticosteroid , 5 mg/day prednisone systemic corticosteroid formulation equivalent 5 mg/day prednisone 1 . A patient enrol OLES need receive acute bolus steroid ( oral injectable ) selflimited illness may continue treatment study follow requirement meet : 1 . Exposure steroid limit 30 consecutive day 2 . The maximal dose steroid ( prednisone equivalent ) must limit 225 mg ( 7.5 mg day 30 day ) 3 . The illness acute nature expect recur remain period study Bisphosphonates , include investigational bisphosphonates Calcitonin Estrogen replacement therapy oral , transdermal intramuscular administration SERM drug , e.g. , tamoxifen , raloxifene , Evista Vaginal application estrogencontaining cream unless dose : 1. conjugate estrogen estradiol : maximum 0.5 g twice week ( total 1.0 g weekly ) 2 . Estrace ( Ogen ) : maximum 1.0 g twice week ( total 2.0 g weekly ) Daily inhale corticosteroid unless dose equivalent &lt; 1200 µg/day beclomethasone Cytostatics , e.g. , azathioprine , recombinant human tumor necrosis fusion ( Fc ) protein , monoclonal antibody tumor necrosis factor ( e.g. , remicade [ infliximab ] Methotrexate 1 . The antimetabolite , methotrexate , interfere DNA synthesis , repair cellular replication use patient participate OLES . In general , immunomodulatory agent antiproliferative activity permit concomitant medication OLES . Intraarticular injection 1 . Patients may receive maximum one intraarticular injection ( ONE JOINT ONLY ) every 6 month participate OLES . The joint injected may different joint every 6 month . The dose corticosteroid inject exceed antiinflammatory equivalent dose Prednisone 40 mg suspension . The dose volume adjust downward appropriate size joint . Provera acceptable concomitant medication use accord label instruction Patients may enrol OLES stabilize follow therapy specify amount time : Thyroid Hormone ( &lt; 0.1 mg/day thyroxine ) therapy least 6 month If take &gt; 0.1 mg/day &lt; 0.2 mg/day , must serum TSH level 1 . &gt; 0.1mU/L . Patients exclude take dos &gt; 0.2 mg/day . 2 . However , patient minimal change Lthyroxine dose &lt; 0.025 mg/day within 6 month baseline visit , new dose least 2 month , patient may enrol study . The patient 's history Lthyroxine must clearly document source document . 3 . If patient require increase thyroid replacement dose , recommend physician caring patient , enrollment OLES , patient must TSH T4 level within 3 month dose change ensure patient become hyperthyroid Stable dosage thiazide least 3 consecutive month C. Laboratory Values Physical Examination Findings : Serum calcium great 10.7 mg/dL ( 2.66 mmol/L ) baseline manage outline Appendix 4 Urinary calcium creatinine ratio great equal 1 baseline manage outline Appendix 5 Elevated total serum alkaline phosphate ( &gt; 400 U/L ) baseline manage outline Appendix 6 except note Latin South American country . Any clinically significant abnormal value judge investigator D. Substance Abuse : Alcohol and/or drug abuse E. Compliance : Suspected confirm poor compliance complete clinical trial evaluation and/or clinical trial require questionnaire</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Post-menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>PTH</keyword>
	<keyword>ALX1-11</keyword>
</DOC>